Medicamen Biotech Ltd-$

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 13/11/2026 to consider and approve the unaudited financial results for the quarter and half year ended on September 30, 2026.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has submitted a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, detailing securities dematerialized/rematerialized during the quarter ended September 30, 2026.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has made a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, related to substantial acquisition of shares by Shivalik Rasayan Ltd and Growel Remedies Ltd.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has approved the allotment of 5,00,000 equity shares at Rs. 530/- per share to a promoter group entity, Shivalik Rasayan Limited, for an aggregate amount of Rs. 26,50,00,000/-, increasing the company's paid-up equity share capital to Rs. 14,06,28,150/-.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has announced a trading plan under SEBI (PIT) Regulations 2015, disclosing a sale of 70,000 equity shares by Director Sanjay Bansal.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd. has announced the voting results of its 33rd Annual General Meeting (AGM) held on September 26, 2026. The meeting was conducted through two-way Video Conferencing (VQ) facility / Other Audio-Visual Means ('OAVM'). The voting results show that all resolutions were passed with 100% approval from the shareholders. The resolutions include the adoption of the audited standalone financial statements for the financial year ended March 31, 2026, the adoption of the audited consolidated financial statements for the financial year ended March 31, 2026, and the re-appointment of Mr. Suresh Kumar Singh as a director liable to retire by rotation.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the announcement of its financial results for the quarter and half year ending September 30, 2026.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd held its 33rd Annual General Meeting on September 26, 2026, through video conferencing, with no material announcements or resolutions passed.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has submitted its Integrated Annual Report for FY 2025-26 and announced its 33rd Annual General Meeting (AGM) to be held on September 26, 2026, through Video Conferencing/Other Audio-Visual Means (VC/OAVM).

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per the provisions of Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has submitted its Integrated Annual Report for FY 2025-26 and announced its 33rd Annual General Meeting (AGM) to be held on September 26, 2026, through Video Conferencing/Other Audio-Visual Means (VC/OAVM).

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd. has announced the notice of its 33rd Annual General Meeting (AGM) to be held on September 26, 2026, through video conferencing. The company has also submitted its integrated annual report for FY 2025-26, which includes the business responsibility and sustainability report.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has fixed September 19, 2026 as the record date for determining the entitlement of members to receive the dividend, if declared at the ensuing AGM.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has announced the fixing of record date as September 19, 2026 for the declaration of final dividend for FY 2025-26. The company has also approved the draft annual report and cost audit report for FY 2025-26. Additionally, the board has taken note of notices/communications received from stock exchanges regarding non-compliance/compliance-related matters.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has announced the publication of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has announced the closure of its Register of Members and Share Transfer Books from September 19, 2026 to September 25, 2026, in connection with the proposed payment of a 10% final dividend. The company has also approved its unaudited financial results for the quarter ended June 30, 2026, and has scheduled its 33rd Annual General Meeting for September 26, 2026.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd announced its financial results for the quarter ended June 30, 2026, with the Board of Directors approving the unaudited financial results (standalone and consolidated) for the quarter. The company also announced the closure of the register of members and share transfer books from September 19 to 25, 2026, in connection with the proposed payment of a final dividend. The Board took note of notices/communications received from stock exchanges regarding non-compliance/compliance-related matters.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has scheduled a Board Meeting on August 14, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026, and other related matters.

Medicamen Biotech Ltd-$

Medicamen Biotech Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended June 30, 2026, detailing securities dematerialized and rematerialized during the period.